Private Management Group Inc. Has $26.04 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Private Management Group Inc. lowered its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 7.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,181,665 shares of the company's stock after selling 92,332 shares during the quarter. Private Management Group Inc. owned about 0.10% of Teva Pharmaceutical Industries worth $26,044,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC raised its holdings in shares of Teva Pharmaceutical Industries by 49.5% in the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company's stock worth $1,130,589,000 after purchasing an additional 20,762,226 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Teva Pharmaceutical Industries by 7,945.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company's stock worth $86,350,000 after purchasing an additional 4,732,374 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Teva Pharmaceutical Industries by 237.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company's stock worth $60,863,000 after buying an additional 2,376,668 shares during the period. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Teva Pharmaceutical Industries by 6.8% in the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company's stock worth $621,337,000 after buying an additional 2,204,623 shares during the period. Finally, State Street Corp lifted its position in Teva Pharmaceutical Industries by 10.0% in the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company's stock worth $351,402,000 after buying an additional 1,778,268 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on TEVA shares. UBS Group decreased their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st. Finally, Barclays reduced their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of "Moderate Buy" and a consensus price target of $23.57.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA traded down $0.49 during midday trading on Friday, reaching $16.80. The stock had a trading volume of 9,620,981 shares, compared to its average volume of 13,051,697. The company has a market capitalization of $19.03 billion, a price-to-earnings ratio of -11.58, a price-to-earnings-growth ratio of 1.43 and a beta of 0.71. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The company's 50-day moving average is $20.05 and its 200 day moving average is $18.50. Teva Pharmaceutical Industries Limited has a 12-month low of $11.83 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 40.20%. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.